Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Cutting-Edge Research on Psoriasis
share announcement

Cutting-Edge Research on Psoriasis

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: 25 October 2024 | Viewed by 1775

Special Issue Editors

Dr. Alessandra Narcisi

E-Mail Website
Guest Editor
1. Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy
Interests: psoriasis; biologics; atopic dermatitis; inflammatory skin diseases; translational research
Special Issues, Collections and Topics in MDPI journals
Dr. Luigi Gargiulo

E-Mail
Guest Editor
1. Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, MI, Italy
2. Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, MI, Italy
Interests: dermatology; psoriasis; atopic dermatitis; biologics; JAK-inhibitors

Special Issue Information

Dear Colleagues,

Psoriasis is a common, chronic, inflammatory, immune-mediated disease, primarily affecting the skin. It is characterized by abnormalities in innate and acquired immunity, hyperproliferation, and abnormal differentiation of epidermal keratinocytes.

Psoriasis is a systemic, multifactorial disease associated with psoriatic arthritis in approximately one-third of patients, so early recognition and effective treatment are critical for patients. ​In addition, people with severe psoriasis are at higher risk for metabolic and cardiovascular disease. The development of new effective treatments for psoriasis has changed the prognosis and the life of many patients around the world, but there is a strong need for more real-world experiences of these drugs

This Special Issue entitled “Cutting-Edge Research on Psoriasis” is now open for submissions, welcoming both original researches and reviews that describe the latest treatment strategies and clinical management approaches related to psoriasis.

Dr. Alessandra Narcisi
Dr. Luigi Gargiulo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • inflammatory skin diseases
  • artificial intelligence
  • systemic treatments
  • dermatopathology
  • biologics
  • anti-IL-23
  • anti-IL-17
  • immunology
  • diagnosis
  • treatment
  • management

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 3531 KiB  
Article
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
by Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Giuseppe Argenziano, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo Giovanni Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Chiara Franchi, Francesca Maria Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo Valerio Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Francesca Sampogna, Massimo Travaglini, Mario Valenti, Antonio Costanzo and Alessandra Narcisiadd Show full author list remove Hide full author list
J. Clin. Med. 2024, 13(2), 495; https://doi.org/10.3390/jcm13020495 - 16 Jan 2024
Cited by 1 | Viewed by 1227
Abstract
Background: Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin-23. It has been approved for moderate-to-severe plaque psoriasis and has shown efficacy and safety in clinical trials and real-world experiences. This study aimed to evaluate the long-term effectiveness, safety, and drug survival [...] Read more.
Background: Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin-23. It has been approved for moderate-to-severe plaque psoriasis and has shown efficacy and safety in clinical trials and real-world experiences. This study aimed to evaluate the long-term effectiveness, safety, and drug survival of risankizumab in a real-life setting. Materials and Methods: We included patients treated with risankizumab from January 2019 to February 2023. A Psoriasis Area and Severity Index score (PASI) was collected at weeks 0, 16, 28, 52, 104, and 156, when available. The occurrence of any adverse events was recorded at each visit. Results: We enrolled 1047 patients. At week 52, a ≥90% improvement in PASI was observed in 81.44% of patients, with a continuous improvement throughout the study (88.99% and 99.07% at weeks 104 and 156, respectively). After three years of treatment, all patients involving the scalp, palms/soles, and genitalia and 95% of patients with nail psoriasis achieved a complete or almost complete skin clearance. No significant safety findings were observed, and 90.73% of the patients were still on treatment after 36 months. Conclusions: This study supports the long-term effectiveness and safety of risankizumab in a real-world setting, even in patients involving difficult-to-treat areas. Full article
(This article belongs to the Special Issue Cutting-Edge Research on Psoriasis)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 842 KiB  
Review
Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition
by Martina Dragotto, Martina D’Onghia, Emanuele Trovato, Linda Tognetti, Pietro Rubegni and Laura Calabrese
J. Clin. Med. 2024, 13(11), 3091; https://doi.org/10.3390/jcm13113091 - 24 May 2024
Viewed by 212
Abstract
Psoriasis is an inflammatory skin disease with a chronic relapsing course and an often-detrimental impact on patients’ quality of life. Thanks to incredible advances in research over the past few decades, the therapeutic armamentarium of psoriasis is now reasonably broad and structured, with [...] Read more.
Psoriasis is an inflammatory skin disease with a chronic relapsing course and an often-detrimental impact on patients’ quality of life. Thanks to incredible advances in research over the past few decades, the therapeutic armamentarium of psoriasis is now reasonably broad and structured, with several therapeutic agents that have demonstrated successful long-term control of this condition. However, there are still unfulfilled gaps resulting from the inherent limitations of existing therapies, which have paved the way for the identification of new therapeutic strategies or the improvement of existing ones. A great deal of attention has recently been paid to the JAK/STAT pathway, playing a crucial role in chronic inflammatory skin diseases, including psoriasis. Indeed, in a disease with such a complex pathogenesis, the possibility to antagonize multiple molecular pathways via JAK/STAT inhibition offers an undeniable therapeutic advantage. However, data from clinical trials evaluating the use of oral JAK inhibitors in immune-mediated disorders, such as RA, have arisen safety concerns, suggesting a potentially increased risk of class-specific AEs such as infections, venous thromboembolism, and malignancies. New molecules are currently under investigation for the treatment of psoriasis, such as deucravacitinib, an oral selective inhibitor that binds to the regulatory domain of TYK2, brepocitinib (PF-06700841) and PF-06826647 that bind to the active site in the catalytic domain. Due to the selective TYK2 blockade allowing the inhibition of key cytokine-mediated signals, such as those induced by IL-12 and IL-23, anti-TYK2 agents appear to be very promising as the safety profile seems to be superior compared with pan-JAK inhibitors. The aim of our review is to thoroughly explore the rationale behind the usage of JAK inhibitors in PsO, their efficacy and safety profiles, with a special focus on oral TYK2 inhibitors, as well as to provide a forward-looking update on novel therapeutic strategies targeting the TYK2 pathway in psoriasis. Full article
(This article belongs to the Special Issue Cutting-Edge Research on Psoriasis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop